ipharmacenter Consulting services

Roche’s BTK inhibitor fenebrutinib delivers strong efficacy in relapsing multiple sclerosis, opening up a potential multi‑billion‑dollar revenue opportunity for the company Roche’s BTK inhibitor fenebrutinib has generated a third consecutive Phase III success in multiple sclerosis, strengthening its positioning as a potential first-in-class option across both relapsing and progressive forms of the disease. What clinical benefits fenebrutinib show in clinical trials? In the la

The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the first licensed treatment for vitiligo to be used in the NHS, providing a new option for more than 80,000 people in England living with the condition. Vitiligo is a chronic autoimmune disorder in which the immune system attacks melanocytes, the cells responsible for skin pigmentation. This leads to pale or white patches on the skin, which can have a considerable effect on